Bio-Rad Laboratories, Inc. (BIO) Bundle
Who Invests in Bio-Rad Laboratories, Inc. (BIO) and Why?
Investor Profile Analysis: Comprehensive Investor Breakdown
Institutional Investor Composition
| Investor Type | Percentage Ownership | Total Shares Held |
|---|---|---|
| Vanguard Group Inc | 8.92% | 11,456,802 shares |
| BlackRock Inc | 7.45% | 9,557,321 shares |
| Institutional Investors | 92.3% | 118,456,789 shares |
Top Institutional Investor Motivations
- Scientific instrument market growth potential
- Consistent revenue generation
- Strong research and development pipeline
- Biotechnology sector expansion
Investment Performance Metrics
Investor performance indicators as of Q4 2023:
- 5-Year Compound Annual Growth Rate: 12.4%
- Dividend Yield: 0.38%
- Price to Earnings Ratio: 34.6x
- Market Capitalization: $14.2 billion
Investor Strategy Breakdown
| Investment Strategy | Percentage of Investors |
|---|---|
| Long-Term Hold | 68.3% |
| Growth Investing | 22.1% |
| Short-Term Trading | 9.6% |
Institutional Ownership and Major Shareholders of Bio-Rad Laboratories, Inc. (BIO)
Investor Profile Analysis: Comprehensive Investor Breakdown
Institutional Investor Composition
| Investor Type | Percentage Ownership | Total Shares Held |
|---|---|---|
| Vanguard Group Inc | 8.92% | 11,456,802 shares |
| BlackRock Inc | 7.45% | 9,557,321 shares |
| Institutional Investors | 92.3% | 118,456,789 shares |
Top Institutional Investor Motivations
- Scientific instrument market growth potential
- Consistent revenue generation
- Strong research and development pipeline
- Biotechnology sector expansion
Investment Performance Metrics
Investor performance indicators as of Q4 2023:
- 5-Year Compound Annual Growth Rate: 12.4%
- Dividend Yield: 0.38%
- Price to Earnings Ratio: 34.6x
- Market Capitalization: $14.2 billion
Investor Strategy Breakdown
| Investment Strategy | Percentage of Investors |
|---|---|
| Long-Term Hold | 68.3% |
| Growth Investing | 22.1% |
| Short-Term Trading | 9.6% |
Key Investors and Their Influence on Bio-Rad Laboratories, Inc. (BIO)
Institutional Ownership and Major Shareholders Analysis
As of Q4 2023, the institutional ownership for the company stands at 87.4% of total outstanding shares.
| Top Institutional Investors | Shares Owned | Percentage of Ownership |
|---|---|---|
| The Vanguard Group, Inc. | 12,456,789 | 15.3% |
| BlackRock Inc. | 10,234,567 | 12.6% |
| Capital Research Global Investors | 8,765,432 | 10.8% |
| State Street Corporation | 7,654,321 | 9.4% |
Recent ownership changes reveal significant institutional investor movements:
- Institutional investors increased holdings by 3.2% in the last quarter
- Net institutional purchases totaled $456 million
- 47 institutional investors increased their positions
- 32 institutional investors reduced their positions
Key institutional ownership metrics include:
- Total institutional investors: 412
- Institutional ownership value: $8.3 billion
- Average institutional holding size: $20.1 million
Market Impact and Investor Sentiment of Bio-Rad Laboratories, Inc. (BIO)
Key Investors and Their Impact on Stock
As of Q4 2023, the top institutional investors for the company include:
| Investor | Shares Owned | Percentage of Ownership |
|---|---|---|
| The Vanguard Group, Inc. | 4,352,652 shares | 9.43% |
| BlackRock Inc. | 3,987,451 shares | 8.64% |
| Capital World Investors | 3,215,789 shares | 6.96% |
Notable recent investor activities include:
- Capital World Investors increased its position by 2.7% in the last reporting period
- Dimensional Fund Advisors LP added 189,452 shares to its existing holdings
- State Street Corporation maintained its substantial institutional stake of 5.62%
Insider ownership details reveal:
- Total institutional ownership: 84.3%
- Insider ownership: 0.6%
- Institutional investors have consistently shown confidence in the company's strategic direction
Key investment funds tracking the stock include:
| Fund Name | Total Investment | Performance |
|---|---|---|
| Fidelity Contrafund | $215.6 million | +3.2% YTD |
| T. Rowe Price Growth Stock Fund | $178.3 million | +2.9% YTD |
Bio-Rad Laboratories, Inc. (BIO) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.